Currently, there are 41.44M common shares owned by the public and among those 30.74M shares have been available to trade.
The company’s stock has a 5-day price change of -24.62% and -22.94% over the past three months. LPTX shares are trading -84.07% year to date (YTD), with the 12-month market performance down to -89.25% lower. It has a 12-month low price of $0.22 and touched a high of $4.79 over the same period. LPTX has an average intraday trading volume of 2.16 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -20.28%, -19.06%, and -81.28% respectively.
Institutional ownership of Leap Therapeutics Inc (NASDAQ: LPTX) shares accounts for 21.56% of the company’s 41.44M shares outstanding.
It has a market capitalization of $12.80M and a beta (3y monthly) value of -0.22. The earnings-per-share (ttm) stands at -$1.70. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.92% over the week and 5.92% over the month.
Earnings per share for the fiscal year are expected to increase by 38.67%, and 52.25% over the next financial year. EPS should shrink at an annualized rate of 32.77% over the next five years, compared to 34.28% over the past 5-year period.
Looking at the support for the LPTX, a number of firms have released research notes about the stock. Robert W. Baird stated their Neutral rating for the stock in a research note on January 29, 2025, with the firm’s price target at $9-$1.25. Rodman & Renshaw was of a view on June 28, 2024 that the stock is Buy, while Mizuho gave the stock Buy rating on October 04, 2021, issuing a price target of $6. Robert W. Baird on their part issued Outperform rating on June 04, 2021.
